The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: Implications in myasthenia gravis
Keywords: Myasthenia gravis; Complement; Decay accelerating factor (DAF); Regulatory polymorphism; Prednisone; Muscle; Post-transcriptional regulation; Methotrexate; Cyclosporine; Azathioprine;